A Trial of Text-Message-Based Engagement for Well-Child Visits
Launched by WAYMARK · Nov 18, 2024
Trial Information
Current as of August 20, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
This clinical trial is looking at how different ways of sending reminders can help get children to attend their Well-Child Visits, which are important check-ups for kids from birth to age 21. The researchers want to find out if sending text messages (SMS) is more effective than the usual way of reminding families about these visits. They will also test if adding help with scheduling appointments along with the text reminders makes a difference in getting kids to see their doctor.
To participate in this study, families need to have children aged 0-21 who haven’t had a Well-Child Visit in the last year and are eligible for outreach through their Medicaid health plan. Participants will be randomly assigned to one of three groups: one will receive regular reminders, another will get text message reminders, and the third will receive both text reminders and help scheduling their appointments. The trial is not yet recruiting, but once it starts, families can expect to receive reminders based on their assigned group, and their appointment attendance will be tracked to see which method works best.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Patients aged 0-21 years old who have not had a pediatric well-child visit in the past year
- • 2. Patients for whom the care team is authorized to conduct outreach per the patient's Medicaid health plan
- • 3. Patients with a phone number in health plan eligibility file
- Exclusion Criteria:
- • 1. Patients who have opted out of receiving text/SMS communications
- • 2. Patients without the ability to receive text/SMS messages due to lack of valid phone number or active phone
- • 3. Patients who have requested no contact from their healthcare provider or health plan
About Waymark
Waymark is an innovative clinical trial sponsor dedicated to advancing medical research through the development and execution of transformative clinical studies. With a focus on enhancing patient outcomes and streamlining trial processes, Waymark leverages cutting-edge technology and a patient-centric approach to facilitate efficient data collection and analysis. Committed to collaboration with healthcare providers and regulatory bodies, Waymark aims to accelerate the development of new therapies while ensuring the highest standards of safety and efficacy in clinical research.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
San Francisco, California, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported